2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-77537
    7-Deazaxanthine 39929-79-8
    7-Deazaxanthine (7DX) is an inhibitor of thymidine phosphorylase (TPase). 7-Deazaxanthine inhibits TPase reaction in a concentration-dependent manner with an IC50 value of 40 μM. 7-Deazaxanthine also has a significant angiogenesis inhibitory effect.
    7-Deazaxanthine
  • HY-B1209
    Etofylline 519-37-9 99.72%
    Etofylline (7-(β-Hydroxyethyl) theophylline) is an oral bronchodilator with anti-inflammatory effects. Etofylline inhibits phosphodiesterase and prevents the degradation of cAMP (cyclic adenosine monophosphate), leading to smooth muscle relaxation, reducing inflammatory responses and improving respiratory function. Etofylline affects the development of zebrafish embryos.
    Etofylline
  • HY-B1216
    Oxeladin citrate 52432-72-1 ≥98.0%
    Oxeladin citrate is an orally active and brain-penetrant cough suppressant as well as a selective sigma 1 receptor agonist (Ki = 25 nM). Oxeladin can be used for pulmonary diseases and stroke research.
    Oxeladin citrate
  • HY-N0899
    Wilforine 11088-09-8 99.47%
    Wilforine is a sesquiterpene pyridine alkaloid; important bioactive compound in T.
    Wilforine
  • HY-N4081
    Dracorhodin 643-56-1
    Dracorhodin, the main component in sanguis draconis, is a flavylium compound belonging to the anthocyanin family. Dracorhodin can induce vasodilatation.
    Dracorhodin
  • HY-113667
    ASN04885796 1032892-26-4 99.61%
    ASN04885796 (compound IV) is an GPR17 activator with an EC50 of 2.27 nM for GPR17 induced GTPγS binding. ASN04885796 has neuroprotective property and can be used for research of neurological diseases.
    ASN04885796
  • HY-124577
    MDI-2268 1609176-50-2 99.73%
    MDI-2268 is an inhibitor of plasma kallikrein inhibitor 1 (PAI-1). MDI-2268 has good antithrombotic properties and regulates blood coagulation and fibrinolysis process by enhancing fibrinolysis. MDI-2268 can be used in research areas such as deep vein thrombosis.
    MDI-2268
  • HY-148506
    5'-ODMT cEt m5U Phosphoramidite (Amidite) 1197033-22-9 99.25%
    5'-ODMT cEt m5U Phosphoramidite Amidite is a locked nucleic acid (LNA) analog. 5'-ODMT cEt m5U Phosphoramidite Amidite shows excellent safety and antisense activity in mice.
    5'-ODMT cEt m5U Phosphoramidite (Amidite)
  • HY-148542
    EpoY 245660-13-3 98.8%
    EpoY (SD-142) acts as an irreversible inhibitor of the brain's primary tubulin tyrosine carboxypeptidase (TCP), a complex formed by vasohibin-1 (VASH1) and the small vasohibin binding protein (SVBP). By inhibiting TCP with an IC50 value of approximately 500 nM, EpoY effectively decreases levels of detyrosinated alpha-tubulin, which is crucial for microtubule dynamics and neuronal differentiation. This inhibition leads to significant differentiation defects and has been linked to underlying issues associated with cancer and cardiomyopathies.
    EpoY
  • HY-156371
    MIPS-21335 2569296-51-9 99.61%
    MIPS-21335 is an PI3KC2α inhibitor (IC50: 7 nM). MIPS-21335 also inhibits PI3KC2β, p110α, p110β and p110δ (IC50: 0.043, 0.140, 0.386, 0.742 μM). MIPS-21335 has antithrombotic effect.
    MIPS-21335
  • HY-B0006A
    Carvedilol phosphate hemihydrate 610309-89-2 99.94%
    Carvedilol phosphate hemihydrate (BM 14190 phosphate hemihydrate) is a non-selective β/α-1 blocker. Carvedilol phosphate hemihydrate inhibits lipid peroxidation with an IC50 of 5 μM. Carvedilol phosphate hemihydrate is a multiple action antihypertensive agent with potential use in angina and congestive heart failure. Carvedilol phosphate hemihydrate is an autophagy inducer that inhibits the NLRP3 inflammasome.
    Carvedilol phosphate hemihydrate
  • HY-N0455R
    L-Arginine (Standard) 74-79-3
    L-Arginine (Standard) is the analytical standard of L-Arginine. This product is intended for research and analytical applications. L-Arginine ((S)-(+)-Arginine) is the substrate for the endothelial nitric oxide synthase (eNOS) to generate NO. L-Arginine is transported into vascular smooth muscle cells by the cationic amino acid transporter family of proteins where it is metabolized to nitric oxide (NO), polyamines, or L-proline. L-Arginine is a potent vasodilator, and can be used to induce experimental acute pancreatitis.
    L-Arginine (Standard)
  • HY-106591A
    4-Vinylcyclohexene dioxide 106-87-6 ≥98.0%
    4-Vinylcyclohexene dioxide is a metabolite of 4-vinylcyclohexene that can specifically destroy oocytes in primordial and primary follicles of rats and mice. 4-Vinylcyclohexene dioxide induces apoptosis in rat cells is associated with activation of a caspase-mediated cascade.
    4-Vinylcyclohexene dioxide
  • HY-W010451
    1,2,4-Trihydroxybenzene 533-73-3 ≥98.0%
    1,2,4-Trihydroxybenzene (Hydroxyhydroquinone), a by-product of coffee bean roasting, increases intracellular Ca2+ concentration in rat thymic lymphocytes.
    1,2,4-Trihydroxybenzene
  • HY-W014841
    Sodium hippurate, 98% 532-94-5 99.91%
    Sodium hippurate, 98% is an orally active metabolite. Sodium hippurate, 98% can be produced by intestinal microorganisms from the metabolism of polyphenols, benzoic acid. Sodium hippurate, 98% decreases NRF2, MMP9 and leads to ROS accumulation. Sodium hippurate, 98% activates TGFβ/SMAD signaling. Sodium hippurate, 98% improves hyperuricemia and colitis. Sodium hippurate, 98% can also be used in cardiovascular disease research. .
    Sodium hippurate, 98%
  • HY-W015820
    Phthalide 87-41-2 99.94%
    Phthalide is a chemical scaffold. Phthalide can be used to synthesize a variety of phthalide derivatives including anti-inflammatory agent, antimicrobial, antioxidant and blood-tumor barrier modulators.
    Phthalide
  • HY-120343
    GSK106 1652591-82-6 98.00%
    GSK106 is an inactive control for the selective PAD4 inhibitors, GSK484 and GSK199.
    GSK106
  • HY-14256
    BMS-191095 166095-21-2 98.01%
    BMS-191095 is a selective activator of mitochondrial ATP-sensitive potassium (mitoKATP) channels. BMS-191095 inhibits human platelet aggregation by opening mitochondrial K(ATP) channels.
    BMS-191095
  • HY-14854
    Tecarfarin 867257-26-9 98.65%
    Tecarfarin (ATI-5923) is an orally active and non-competitive vitamin K epoxide reductase (VKOR) antagonist, and impairs the activation of the vitamin K-dependent clotting factors II, VII, IX and X. Tecarfarin has the antithrombotic activity .
    Tecarfarin
  • HY-16751
    Ralinepag 1187856-49-0 99.79%
    Ralinepag is a potent, orally bioavailable and non-prostanoid prostacyclin (IP) receptor agonist, with EC50s of 8.5 nM, 530 nM and 850 nM for human and rat IP receptor and human DP1 receptor, respectively.
    Ralinepag
Cat. No. Product Name / Synonyms Application Reactivity